2023. Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s153. DOI:https://doi.org/10.25251/skin.7.supp.153.